Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
Liệu Pháp Laser Trong Quản Lý Bệnh Võng Mạc Đái Tháo Đường
Tóm tắt
Phù hoàng điểm do tiểu đường là nguyên nhân chính gây giảm thị lực ở những bệnh nhân mắc bệnh tiểu đường. Bài tổng quan này khám phá các phương pháp điều trị bằng laser bên cạnh giao thức quang đông laser điểm/lưới đã được thiết lập, lần đầu tiên được chứng minh trong Nghiên cứu Điều trị Sớm Bệnh Võng Mạc Đái Tháo Đường. Laser vi điểm dưới ngưỡng đã được chứng minh là liệu pháp hỗ trợ hiệu quả kết hợp với tiêm thuốc chống mạch máu trong nội nhãn ở một nhóm bệnh nhân cụ thể, đặc biệt là những người có độ dày võng mạc dưới 400 μm, mà không có nguy cơ xuất hiện điểm mù và mất thị lực có thể xảy ra với laser truyền thống. Do không có sẹo từ loại laser “vô hình” này, laser vi điểm dưới ngưỡng có thể cho phép điều trị sớm hơn trước khi xuất hiện phù hoàng điểm lâm sàng đáng kể, có khả năng ngăn ngừa mất thị lực triệu chứng và tổn thương tế bào cảm quang vĩnh viễn.
Từ khóa
#phù hoàng điểm tiểu đường #liệu pháp laser #bệnh võng mạc #điều trị vi điểm dưới ngưỡng #tiêm thuốc chống mạch máu nội nhãn.Tài liệu tham khảo
National Society to Prevent Blindness. Vision problems in the US: data analysis, definitions, data sources, detailed data tables, analyses, interpretation. New York: National Society to Prevent Blindness; 1980.
Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology. 1984;91(12):1464–74.
Early Treatment of Diabetic Retinopathy Study. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. ETDRS report no. 2. Ophthalmology. 1987;94:761–74.
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 1991;98:766–85.
Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2011;118:609–14. doi:10.1016/j.ophtha.2010.12.033.
Schmidt-Erfurth U, Lang GE, Holz FG, et al. Three-year outcomes of individualized Ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology. 2014;5:1045–53.
Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991;109:1549–51.
Elman MJ, Ayala A, Bressler NM, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5 year randomized clinical results. Ophthalmology. 2015;122(2):375–81.
Luttrull J, Sramek C, Palanker D, et al. Long-term safety, high resolution imaging, and tissue temperature modeling of subvisible diode micropulse photocoagulation for retinovascular macular edema. Retina. 2012;32:375–86.
Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular edema. Br J Ophthalmol. 2005;89:74–80.
Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796–806.
Lewen RM. Subretinal neovascularization complicating laser photocoagulation of diabetic maculopathy. Ophthalmic Surg. 1988;19:734–7.
Lewis H, Schachat AP, Haimann MH, et al. Choroidal neovascularization after laser photocoagulation for diabetic macular edema. Ophthalmology. 1990;97:503–10.
Guyer DR, D’Amico DJ, Smith CW. Subretinal fibrosis after laser photocoagulation for diabetic macular edema. Am J Ophthalmol. 1992;113:652–6.
Shah AM, Bressler NM, Jampol LM. Does laser still have a role in the management of retinal vascular and neovascular diseases? Am J Ophthalmol. 2011;152(3):332–9.
Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology. 1991;98:1594–602.
Writing Committee for the Diabetic Retinopathy Clinical Research. Network comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol. 2007;125(4):469–80.
Dorin G. Evolution of retinal laser therapy: minimum intensity photocoagulation (MIP). Can the laser heal the retina without harming it? In: Seminars in Ophthalmology. 2004. Vol. 19, No. 1–2, p. 62–8.
Mainster MA. Decreasing retinal photocoagulation damage: principles and techniques. In: Seminars in Ophthalmology. 1999. p. 200–9.
Akduman L, Olk RJ. Subthreshold (subvisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME). Ophthalmic Surg Lasers. 1999;30:706–14.
Roider J, Brinkmann R, Wirbelauer C, et al. Subthreshold (retinal pigment epithelium)photocoagulation in macular diseases: a pilot study. Br J Ophthalmol. 2000;84:40–7.
Olk RJ, Akduman L. Minimal intensity diode laser (810 nanometer) photocoagulation (MIP) for diffuse diabetic macular edema (DDME). Sem Ophthalmol. 2001;16:25–30.
Friberg TR, Karatza EC. The treatment of macular disease using a micropulsed and continuous wave 810-nm diode laser. Ophthalmoogy. 1997;104:2030–8.
Moorman CM, Hamilton AM. Clinical applications of the MicroPulse diode laser. Eye. 1999;13:145–50.
Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev. 2012;8:274–84.
Marshall J, Clover G, Rothery S. Some new findings of retinal irradiation by krypton and argon lasers. In: Birngruber R, Gabel V-P, editors. Laser treatment and photocoagulation of the eye. Doc Ophthalmol Proc Series 36. The Hague: Junk; 1984. p. 21–37.
Yamamoto C, Ogata N, Yi X, et al. Immunolocalization of transforming growth factor â during wound repair after laser photocoagulation. Graefes Arch Clin Exp Ophthalmol. 1998;236:41–6.
Yoshimura N, Matsumoto M, Shimizu H, et al. Photocoagulated human retinal pigment epithelial cells produce an inhibitor of vascular endothelial cell proliferation. Invest Ophthalmol Vis Sci. 1995;36:1686–91.
Framme C, Walter A, Prahs P, et al. Structural changes of the retina after conventional laser photocoagulation and selective retina treatment (SRT) in spectral domain OCT. Curr Eye Res. 2009;34:568–79.
Roider J, Michaud N, Flotte T, Birngruber R. Histology of retinal lesions after continuous irradiation and after selective microcoagulation of the retinal pigment epithelium. Ophthalmologe. 1993;90(3):274–8.
Roider J, Liew SHM, Klatt C, et al. Selective retina therapy (SRT) for clinically significant diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248(9):1263–72.
Laursen ML, Moeller F, Sander B, et al. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol. 2004;88:1173–9.
•• Mansouri A, Sampat KM, Malik KJ, et al. Efficacy of subthreshold micropulse laser in the treatment of diabetic macular edema is influenced by pre-treatment central foveal thickness. Eye. 2014;28:1418–24. This article explains the importance of patient selection when deciding who may benefit most from subthreshold micropulse laser. Patient with mild to moderate edema benefit the most, while intravitreal anti-VEGF therapy may be reserved for those with increased central foveal thickness.
Luttrull JK, Spink CA. Serial optical coherence tomography of subthreshold diode micropulse photocoagulation for diabetic macular edema. Opthalmic Surg Lasers Imaging. 2006;37:370–7.
Vujosevic S, Bottega E, Casciano M, et al. Microperimetry and fundus autofluorescence in diabetic macular edema, subthreshold micropulse diode laser versus modified Early Treatment Diabetic Retinopathy Study laser photocoagulation. Retina. 2010;30:903–16.
Lavinksy D, Cardillo JA, Melo LA Jr, et al. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52(7):4314–23.
• Vujosevic S, Martini F, Longhin E, et al. Subthreshold micropulse yellow laser versus subthreshold micropulse infrared laser in center-involving diabetic macular edema: morphologic and functional safety. Retina. 2015;35:1594–603. The safety of Subthreshold Micropulse Yellow laser and Subthreshold Infrared Laser were established at certain parameters without any visible laser spots seen on any imaging modalities.
•• Luttrull JK, Sinclair SH. Safety of transfoveal subthreshold diode micropulse laser for fovea-involving diabetic macular edema in eyes with good visual acuity. Retina. 2014;34:2010–20. The safety of Transfoveal Subthreshold Diode Micropulse laser was established. There was no evidence of any macular damage on any imaging devices. Patients in this study had good visual acuity (20/40 or better) allowing for safe alternative options in the treatment of diabetic macular edema.
Figueira J, Khan J, Nunes S. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular edema. Br J Ophthalmol. 2009;93:1341–4.
Brown JC, Solomon SD, Bressler SB. Detection of diabetic foveal edema. Arch Ophthalmol. 2004;122:330–5.
Channa R, Sophie R, Khwaja AA, et al. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. Eye. 2014;28:269–78.